Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Gross Margin: 2013-2025

Historic Gross Margin for Ocular Therapeutix (OCUL) over the last 13 years, with Sep 2025 value amounting to 10.01%.

  • Ocular Therapeutix's Gross Margin fell 2144.00% to 10.01% in Q3 2025 from the same period last year, while for Sep 2025 it was 7.13%, marking a year-over-year decrease of 2777.00%. This contributed to the annual value of 34.73% for FY2024, which is 412.00% up from last year.
  • As of Q3 2025, Ocular Therapeutix's Gross Margin stood at 10.01%, which was up 599.03% from -2.01% recorded in Q2 2025.
  • In the past 5 years, Ocular Therapeutix's Gross Margin registered a high of 39.21% during Q2 2024, and its lowest value of -32.25% during Q1 2025.
  • Over the past 3 years, Ocular Therapeutix's median Gross Margin value was 31.07% (recorded in 2024), while the average stood at 21.40%.
  • In the last 5 years, Ocular Therapeutix's Gross Margin skyrocketed by 32,055bps in 2021 and then plummeted by 6,332bps in 2025.
  • Over the past 5 years, Ocular Therapeutix's Gross Margin (Quarterly) stood at 25.77% in 2021, then tumbled by 60bps to 25.17% in 2022, then soared by 1,237bps to 37.54% in 2023, then crashed by 100bps to 36.54% in 2024, then slumped by 2,144bps to 10.01% in 2025.
  • Its last three reported values are 10.01% in Q3 2025, -2.01% for Q2 2025, and -32.25% during Q1 2025.